Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 8/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.72 |
| ▸ | POLB | P06746 | 5/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.72 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.72 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | EIF4E | P06730 | 1/20 | 0.71 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883225 | 0.92 | KMT2A (0.83) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL29424240 | 0.91 | MEN1 (0.85) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16639749 | 0.91 | KMT2A (0.72) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL684266 | 0.89 | MEN1 (0.65) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL684546 | 0.86 | ENPP2 (1.00) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16644157 | 0.84 | ENPP2 (0.78) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL29468145 | 0.84 | KMT2A (0.75) | MEN1KMT2APOLBL3MBTL1NPC1 | |
| SCHEMBL29358417 | 0.84 | KMT2A (1.00) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL6393879 | 0.83 | TDP1 (0.74) | ENPP2MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL5146587 | 0.83 | TDP1 (0.74) | ENPP2MEN1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111553-A2 | ANTIBODY-BASED HUMAN LAMP-1 COMPOSITION AND ITS USES | THE GENERAL HOSPITAL CORPORATION (US) | 2025-05-30 | — | — | WO | claimed |
| CN-115057927-B | Peanut allergen Ara h1 specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | claimed |
| CN-115057927-A | Peanut allergen Ara h1 specific nano antibody and application thereof | 南开大学 | 2022-09-16 | — | — | CN | claimed |
| WO-2025111553-A2 | ANTIBODY-BASED HUMAN LAMP-1 COMPOSITION AND ITS USES | THE GENERAL HOSPITAL CORPORATION (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-115057927-B | Peanut allergen Ara h1 specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-115057927-B | Peanut allergen Ara h1 specific nano-antibody and application thereof | 南开大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-115057927-A | Peanut allergen Ara h1 specific nano antibody and application thereof | 南开大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-115057927-A | Peanut allergen Ara h1 specific nano antibody and application thereof | 南开大学 | 2022-09-16 | — | — | CN | disclosed |
| US-11180560-B2 | Compositions and methods to treat solid tumors | WAYNE STATE UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3682947-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | GB006, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | ENPP2 1581/4885MEN1 1586/4885KMT2A 2448/4885 |
| US-11180560-B2 | Compositions and methods to treat solid tumors | ITGB8, MMP8, ITGA8 | ENPP2 1042/4885MEN1 3142/4885KMT2A 2746/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | ENPP2 107/4885MEN1 2635/4885KMT2A 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.